Advance Dx 100 Blood Collection Cards: High Glucose Test Results Hazard
Advance Dx recalls 25-count blood collection cards and 500-pack foil bags due to high glucose test results. Consumers should check product details and contact the company for remedy.
Lower-risk recall
Due to high glucose test results when using the blood collection cards.
Contact the company
What happened, in plain English
Advance Dx is recalling blood collection cards and foil bags that may cause high glucose test results. This could lead to inaccurate blood sugar readings, which might affect health decisions. Read more at govinfonow.com/recall/62241-advance-dx-100-blood-collection-cards-high-glucose-test-results.
Source Summary by GovInfoNow · govinfonow.com/recall/62241-advance-dx-100-blood-collection-cards-high-glucose-test-results · Updated August 19, 2026 · FDA enforcement record: FDA #Z-2237-2021
Cite this page
“Advance Dx 100 Blood Collection Cards: High Glucose Test Results Hazard.” GovInfoNow, updated August 19, 2026. https://govinfonow.com/recall/62241-advance-dx-100-blood-collection-cards-high-glucose-test-results. Based on FDA recall #Z-2237-2021 (https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-2237-2021%22&limit=1).
Why it’s dangerous
The blood collection cards may produce high glucose test results when used with certain blood samples. This could lead to inaccurate blood sugar readings, potentially causing health decisions based on incorrect information.
Who’s affected
People who use these blood collection cards for glucose testing may be affected. Those with diabetes or health conditions requiring regular glucose monitoring are at higher risk.
How to tell if you have this one
Check for product catalog number CMT01 or lot number PPD02102 on the packaging. The product was sold with the reference code REF CMT01.
- Brand
Advance Dx- Category
Medical device
What to do — step by step
Check Product Details
Look for product catalog number CMT01 or lot number PPD02102 on the packaging.
Where it went and when
Where it was distributed
Distributed nationwide; the notice names 2 states.
FDA distribution: “U.S. Nationwide distribution in the states of MD and NC.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Named in the notice: Maryland, North Carolina.
Recall timeline
FDA terminated this recall 2.1 years after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest medical device recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #Z-2237-2021 (July 6, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for Z-2237-2021 to see it in context.
- Plain-language summary written by qwen3:4b on August 19, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.